Abstract
Background: Non-small cell lung cancer is the leading cancer-related cause of death.
Objective: We review the latest therapies for NSCLC with EGFR and ELM4-ALK mutations as well as the most relevant studies and promising patents.
Method: A literature search of PubMed database was carried out to identify recent Clinical Trials using EGFR therapies and novel patents involving diagnosis and therapies on NSCLC. We conducted a search to find new therapy strategies, new biomarkers, and selected five patents we find relevant.
Results: Over the last few years, identification of cancer harboring epidermal growth factor receptor mutations (EGFR) or chromosomal rearrangements of anaplastic lymphoma kinase (ALK) led to new ways in classifying and treating NSCLC. On the other hand, acquired resistance are a constantly challenge in the management of patients with these mutations and new drugs options are in development to improve and amplify treatment strategies.
Conclusions: Currently, EGFR TKIs (e.g.: erlotinib, gefitinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced NSCLC outcomes. To understand the disease molecular profile is mandatory to define the best approach for each patient.
Keywords: Afatinib, EGFR, ELM4-ALK, erlotinib, geftinib, non-small cell lung cancer, osimertinib, patent.
Recent Patents on Anti-Cancer Drug Discovery
Title:EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer
Volume: 11 Issue: 4
Author(s): Ramon Andrade De Mello*, Davi J. J. Liu, Pedro N. Aguiar and Hakaru Tadokoro
Affiliation:
- Department of Biomedical Sciences and Medicine, University of Algarve, Campus de Gambelas, Ala nascente, Edifício 7, 3º Andar, 8005-139, Faro, Portugal.,Portugal
Keywords: Afatinib, EGFR, ELM4-ALK, erlotinib, geftinib, non-small cell lung cancer, osimertinib, patent.
Abstract: Background: Non-small cell lung cancer is the leading cancer-related cause of death.
Objective: We review the latest therapies for NSCLC with EGFR and ELM4-ALK mutations as well as the most relevant studies and promising patents.
Method: A literature search of PubMed database was carried out to identify recent Clinical Trials using EGFR therapies and novel patents involving diagnosis and therapies on NSCLC. We conducted a search to find new therapy strategies, new biomarkers, and selected five patents we find relevant.
Results: Over the last few years, identification of cancer harboring epidermal growth factor receptor mutations (EGFR) or chromosomal rearrangements of anaplastic lymphoma kinase (ALK) led to new ways in classifying and treating NSCLC. On the other hand, acquired resistance are a constantly challenge in the management of patients with these mutations and new drugs options are in development to improve and amplify treatment strategies.
Conclusions: Currently, EGFR TKIs (e.g.: erlotinib, gefitinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced NSCLC outcomes. To understand the disease molecular profile is mandatory to define the best approach for each patient.
Export Options
About this article
Cite this article as:
De Mello Andrade Ramon*, Liu J. J. Davi, Aguiar N. Pedro and Tadokoro Hakaru, EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer, Recent Patents on Anti-Cancer Drug Discovery 2016; 11 (4) . https://dx.doi.org/10.2174/1574892811666160803090944
DOI https://dx.doi.org/10.2174/1574892811666160803090944 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Application of Carbon Nanotubes In Drug Delivery of Non-cancerous Diseases: A Review
Current Pharmaceutical Design Biological Activities and Docking Studies on Novel Bis 1,4-DHPS Linked to Arene Core via Ether or Ester Linkage
Letters in Drug Design & Discovery Mitochondria-Targeted Antioxidants as a Therapeutic Strategy for Protecting Endothelium in Cardiovascular Diseases
Current Medicinal Chemistry Angiotensin Peptides and Lung Cancer
Current Cancer Drug Targets Helper T Cells Point the Way to Specific Immunotherapy for Autoimmune Disease
Cardiovascular & Hematological Disorders-Drug Targets Systemic Treatment of Chest Tumors: Highlighting Some Differences Between Eastern and Western Countries
Current Cancer Therapy Reviews Anti-Angiogenic and Anti-Inflammatory Effects of Statins: Relevance to Anti-Cancer Therapy
Current Cancer Drug Targets Xanthohumol: A Metabolite with Promising Anti-Neoplastic Potential
Anti-Cancer Agents in Medicinal Chemistry Depsipeptide (FK228) as a Novel Histone Deacetylase Inhibitor: Mechanism of Action and Anticancer Activity
Mini-Reviews in Medicinal Chemistry Pulmonary Neuroendocrine Cell System in Health and Disease
Current Respiratory Medicine Reviews The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors
Current Cancer Therapy Reviews Properties of Oils From Plantain Pseudostem Biotransformed Using Crude Local Enzyme Sources: A Comparison of Poultry Feed Oil
Recent Patents on Food, Nutrition & Agriculture Chitosan - A Potential Polymer to Prepare Anticancer Drug Delivery Systems: Patent Review
Recent Patents on Anti-Cancer Drug Discovery <sup>99m</sup>Tc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors of the Lung (and in other Malignant and Benign Pulmonary Diseases)
Current Radiopharmaceuticals To Be, or Not To Be: That is the Question-Lineage Commitment in Hematopoiesis
Current Immunology Reviews (Discontinued) Aminophosphonate Metal Complexes of Biomedical Potential
Current Medicinal Chemistry A Review on Synthesis, Anticancer and Antiviral Potentials of Pyrimidine Derivatives
Current Bioactive Compounds HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery Population Based Helicobacter pylori Screening and Eradication: Advances Versus Side Effects
Current Pharmaceutical Design Xanthone Derivatives: New Insights in Biological Activities
Current Medicinal Chemistry